News

Kyowa Hakko Kirin's Parkinson's therapy, Nourianz (istradefylline), gains FDA approval as an add-on to levodopa/carbidopa.

Radicut/Radicava (edaravone), shown to slow the progression of ALS, is now approved for patients in China.

Orkambi and Symkevi have been rejected by the Scotland Medicines Consortium (SMC) due to their conclusion that the costs outweigh the benefits.

Vitrakvi (larotrectinib) recommended by the CHMP for approval in the EU.

MN-166 (ibudilast) will be part of the Phase III clinical trial on progressive multiple sclerosis subjects with secondary progressive MS without relapses. 

New skin cancer medicine now approved in the EU for adults with metastatic or locally advanced cutaneous squamous cell carcinoma.

Phase 2 clinical trial shows that ibudilast is linked to a 48% slowing in the progression of brain atrophy compared to placebo for patients with progressive MS.

Vyndaqel (tafamidis) is now approved in the U.S. after study showed increased survivorship rate and reduced hospital time due to heart related problems.

Approval for next phase of clinical trials puts ALS patients one step closer to accessing new treatment shown to slow disease progression.

Based on promising results from phase III clinical trials, Health Canada has decided to extend the use of Kalydeco (ivacaftor) to include children aged 1 to 2 years. 

A recent clinical trial indicates that Symkevi/Symdeko (tezacaftor/ivacaftor) can safely and effectively loosen thick, sticky mucus for children 6-11 years old.

The new site-agnostic cancer medicine, Vitrakvi (larotrectinib), gets accelerated approval from the U.S. Food and Drug Administration (FDA).

CHMP's assessment supports EMA's approval of non-small cell lung cancer (NSCLC) medicine, Vizimpro (dacomitinib).

Phase III trial shows that Copiktra (duvelisib) may be an option for patients with relapsed or refractory chronic lymphocytic leukaemia and small lymphocytic lymphoma.

Onpattro (patisiran) is a first-in-class treatment that slows down the progression of hereditary transthyretin amyloidosis (hATTR).

After failing to show a clear benefit over chemotherapy on its own, both the FDA and EMA do not recommend Lartruvo (olaratumab) for use in combination with chemotherapy for new STS patients.

Over 50 countries have approved Spinraza (nusinersen), but not all have made it available to the patients who need it.

New medicine shows statistically significant improvements for prostate cancer patients.

A new biosimilar, Truxima (rituximab), shows comparable results to the reference medicine, Rituxan (rituximab), and takes FDA one step further toward expanding patient access to medicines.

Positive news for patients with early-stage FAP; results from a Portuguese study show that a liver transplant or Vyndaqel may extend survivability.

Zolgensma (onasemnogene abeparvovec-xxxx) to receive priority review by FDA as a one-time treatment of type 1 spinal muscular atrophy (SMA).

Australia provides reimbursement for cystic fibrosis medicine.

The European Commission has approved Alunbrig (brigatinib) for the treatment of a specific type of lung cancer.

A late-stage study testing Bavencio (avelumab) has failed to meet its primary endpoints in patients with certain forms of ovarian cancer.

In an exploratory study Ocrevus (ocrelizumab) slowed down loss of function in the upper extremities for patients with primary progressive multiple sclerosis (PPMS).

How two professors imagine a better world for stakeholders in the medical industry. 

"These results offer a leap in understanding about this disease that provides a genetically based framework for designing clinical trials to develop more effective treatments of MPAL," 

"In short, it will help produce drugs where we can be far more confident about where modifications are being made, so that side effects can be minimized in the future"

Researchers report a successful classification of triple breast cancer patients, which for the first time, would allow doctors to discern between those who can be cured and those who might suffer a relapse.